Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Boehringer Ingelheim to sell US injectable generics business to Hikma for up to $300 million
Boehringer Ingelheim to sell US injectable generics business to Hikma for up to $300 million
Boehringer Ingelheim to sell US injectable generics business to Hikma for up to $300 million
Submitted by
admin
on May 28, 2014 - 10:07am
Source:
First Word Pharma
News Tags:
Boehringer Ingelheim
Hikma
injectables
M&A
Headline:
Boehringer Ingelheim to sell US injectable generics business to Hikma for up to $300 million
Do Not Allow Advertisers to Use My Personal information
